AR026086A1 - METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-DI-PROPILAMINO-TETRAHIDROTETRALINA - Google Patents

METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-DI-PROPILAMINO-TETRAHIDROTETRALINA

Info

Publication number
AR026086A1
AR026086A1 ARP000105496A ARP000105496A AR026086A1 AR 026086 A1 AR026086 A1 AR 026086A1 AR P000105496 A ARP000105496 A AR P000105496A AR P000105496 A ARP000105496 A AR P000105496A AR 026086 A1 AR026086 A1 AR 026086A1
Authority
AR
Argentina
Prior art keywords
disease
tetrahydrotetralin
propylamino
keto
compound
Prior art date
Application number
ARP000105496A
Other languages
Spanish (es)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR026086A1 publication Critical patent/AR026086A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se refiere a un método para tratar el mal de parkinson a través de la administracion de (-)-5-ceto-2-N, N-di-n-propilamino-tetrahidrotetralina. Lasenfermedades degenerativas se vuelven más frecuentes en la poblacion en proceso de envejecimiento. Unaenfermedad neurovegetativa que típicamente aparece entrelos 50 y los 80 anos es el mal de parkinson. Dicho mal e sun desorden que se produce en el cerebro y produce temblores y dificultad para caminar, moverse ycoordinar. Dicha enfermedad es provocada por un deterioro de las neuronas. Dicha enfermedad es provocada por un deterioro de las neuronas que contienendopamina en la zona compacta de la sustancia nigra del cerebro. La dopamina es un neurotransmisor químico utilizado por las células del cerebro para transmitirimpulsos que controlen o modulen el movimiento de los musculos perifericos. Los tratamientos apuntan típicamente a controlar los síntomas que provocan el malde Parkinson, principalmente a través del reemplazo de la dopamina, ya sea con L-DOPA que se metaboliza como dopamina, o la administracion de agentes químicosque estimulán los receptores de dopamina. Un compuesto que es (-)-5-ceto-2-N, N-di-n-propilamino-tetrahidrotetralina. Un método para tratar el mal de Parkinsonen pacientes que necesitan dicho tratamiento, este método comprende el hecho de administrar al paciente una cantidad terapéuticamente efectiva de(-)-5-ceto-2-N, N-di-n-propilamino-tetrahidrotetralina o una sal farmacéuticamente aceptable de lo mismo. Dicho método donde el compuesto que se administra eshidrocloruro de (-)-5-ceto-2-N, N-di-n-propilamino-tetrahidrotetralina. Dicho método donde el compuesto se administra en forma oral. Un método para producir(-)-5, 6-dihidroxi-2-N, N-di-n-propilaminotetralina en un mamífero que comprende el hecho de administrarle al mamífero una cantidad efectiva de (-)-5-ceto-2-N,N-di-n-propilamino-tetrahidrotetralina o una sal farmacéuticamente aceptable del mismo. Dicho método donde al compuesto que se administraes hidrocloruro de(-)-5-ceto-2, N-di-n-propilamino-tetrahidrotetralina. Dicho método donde el compuesto se administra en forma oral. Un proceso para preparar un (-).isomero deIt refers to a method of treating parkinson's disease through the administration of (-) - 5-keto-2-N, N-di-n-propylamino-tetrahydrotetralin. Degenerative diseases become more frequent in the aging population. A neurovegetative disease that typically appears between the ages of 50 and 80 is Parkinson's disease. Said badly and sun disorder that occurs in the brain and produces tremors and difficulty walking, moving and coordinating. This disease is caused by a deterioration of neurons. This disease is caused by a deterioration of the neurons containing pamine in the compact area of the nigra substance of the brain. Dopamine is a chemical neurotransmitter used by brain cells to transmit impulses that control or modulate the movement of peripheral muscles. Treatments typically aim to control the symptoms that cause Parkinson's disease, mainly through the replacement of dopamine, either with L-DOPA that is metabolized as dopamine, or the administration of chemical agents that stimulate dopamine receptors. A compound that is (-) - 5-keto-2-N, N-di-n-propylamino-tetrahydrotetralin. A method of treating Parkinson's disease in patients who need such treatment, this method comprises administering to the patient a therapeutically effective amount of (-) - 5-keto-2-N, N-di-n-propylamino-tetrahydrotetralin or a pharmaceutically acceptable salt of the same. Said method wherein the compound that is administered is (-) - 5-keto-2-N, N-di-n-propylamino-tetrahydrotetralin hydrochloride. Said method where the compound is administered orally. A method of producing (-) - 5,6-dihydroxy-2-N, N-di-n-propylaminotetralin in a mammal comprising administering to the mammal an effective amount of (-) - 5-keto-2- N, N-di-n-propylamino-tetrahydrotetralin or a pharmaceutically acceptable salt thereof. Said method where to the compound that is administered (-) - 5-keto-2, N-di-n-propylamino-tetrahydrotetralin hydrochloride. Said method where the compound is administered orally. A process to prepare a (-). Isomer of

ARP000105496A 1999-10-20 2000-10-19 METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-DI-PROPILAMINO-TETRAHIDROTETRALINA AR026086A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16071699P 1999-10-20 1999-10-20

Publications (1)

Publication Number Publication Date
AR026086A1 true AR026086A1 (en) 2002-12-26

Family

ID=22578122

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105496A AR026086A1 (en) 1999-10-20 2000-10-19 METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-DI-PROPILAMINO-TETRAHIDROTETRALINA

Country Status (8)

Country Link
AR (1) AR026086A1 (en)
AU (1) AU1209501A (en)
CO (1) CO5251402A1 (en)
GT (1) GT200000182A (en)
PA (1) PA8505301A1 (en)
PE (1) PE20010746A1 (en)
SV (1) SV2001000202A (en)
WO (1) WO2001028977A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001438D0 (en) * 2000-04-18 2000-04-18 Axon Chemicals Bv New chemical compounds and their use in therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2065450A1 (en) * 1989-07-05 1991-01-06 James V. Peck Substituted 2-aminotetralins
US6187808B1 (en) * 1998-07-28 2001-02-13 Warner-Lambert Company Hexahydro-naphthalenone oximes and hydrazones

Also Published As

Publication number Publication date
SV2001000202A (en) 2001-10-16
CO5251402A1 (en) 2003-02-28
AU1209501A (en) 2001-04-30
PA8505301A1 (en) 2002-12-30
GT200000182A (en) 2002-04-12
PE20010746A1 (en) 2001-07-27
WO2001028977A1 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
Snyder Amphetamine psychosis: a" model" schizophrenia mediated by catecholamines
JP4154237B2 (en) Novel use of the peptide class of compounds to treat allodynia and various other types of chronic or phantom limb pain
CN1170544C (en) Use of xenon for treating neurointoxications
Gomez-Mancilla et al. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys.
Gibb et al. Pathological report of four patients presenting with cranial dystonias
PT1900362E (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
Patti et al. Effects of rehabilitation therapy on parkinsonians' disability and functional independence
JP2024516421A (en) MDMA enantiomers
BRPI0414347A (en) combination comprising an alpha-2-delta ligand and an ssri and / or snri for treatment of depression and anxiety disorders
CN1293573A (en) Methods of treating tardive dyskinesia and other movement disorders
JP5030553B2 (en) Pharmaceuticals for treating dry mice and / or salivary secretion disorders
MXPA01009963A (en) Method for the treatment of neurological or neuropsychiatric disorders.
DE60218193D1 (en) USE OF 2-OXO-1-PYRROLIDINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF DYSKINESIA
BRPI0614701A2 (en) Uses of a Compound to Improve Vigilance and Pharmaceutical Compositions
ES2649492T3 (en) (S) -pirlindole or its pharmaceutically acceptable salts for use in medicine
Kaur et al. Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
Sandyk et al. Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's Disease
AR026086A1 (en) METHOD FOR TREATING PARKINSON EVIL THROUGH THE ADMINISTRATION OF (-) - 5-CETO-2-N, N-DI-PROPILAMINO-TETRAHIDROTETRALINA
Sandyk A drug naive parkinsonian patient successfully treated with weak electromagnetic fields
Roe From DOPA to Parkinson's disease: the early history of dopamine research
Sandyk Resolution of dysarthria in multiple sclerosis by treatment with weak electromagnetic fields
Lloyd et al. Catecholamines in regulation of motor function
Giamberardino et al. Effects of spasmolytic and/or non-steroidal antiinflammatory drugs on muscle hyperalgesia of ureteral origin in rats
KR20020015609A (en) Use of myricetin as an inhibitor for serotonin N-acetyltransferase